

# Progressing our Expansive Pipeline

RETINAL					Rights
NGM621	Anti-Complement C3 Antibody	Geographic Atrophy	PHASE 2	Enrolling	Merck option at PoC; if optioned, NGM to receive milestones + double-digit royalties <u>or</u> up to 50% profit/cost share <sup>1</sup>

  

ONCOLOGY					
NGM120	GFRAL Antagonistic Antibody	Cancer & Cancer-related Cachexia	PHASE 1A/1B	Ph1a/1b Interim Dose Finding Data Expected in 2H21	Global
		Metastatic Pancreatic Cancer & Cancer-related Cachexia	PHASE 2	Placebo-controlled Expansion Enrolling	Global
NGM707	ILT2/ILT4 Dual Antagonist Antibody	Advanced Solid Tumors	PHASE 1/2	Enrolling	Global
NGM438	LAIR1 Antagonist Antibody	Advanced Solid Tumors	IND-ENABLING STUDIES	Ph1 Initiation Expected 1H22	Global

  

LIVER & METABOLIC DISEASES					
MK-3655 (NGM313)	FGFR1c/KLB Agonistic Antibody	NASH F2/F3	PHASE 2B	Enrolling	Merck optioned at PoC; NGM to receive milestones + double-digit royalties <u>or</u> up to 50% profit/cost share <sup>1</sup>
Aldafermin	FGF19 Analog	NASH F4	PHASE 2B	Enrolling	Global

<sup>1</sup> At NGM's option at Phase 3

NASH = non-alcoholic steatohepatitis; FGF = fibroblast growth factor; KLB = klotho beta; C3 = Component 3; GFRAL = glial cell-derived neurotrophic factor receptor alpha-like; ILT2 = Immunoglobulin-like transcript 2; ILT4 = Immunoglobulin-like transcript 4; LAIR1 = Leukocyte-associated immunoglobulin-like receptor 1; stage 2 or 3 or 4 liver fibrosis (F2/F3/F4); PoC = proof of concept